The panel aims to maintain a list of major developments for the panel, educational opportunities and changes within the NHS that relate to immunoglobulins. These are listed here. Please contact the panel if you would like any further information.
Educational events
The EOEIAP hosts an annual one-day conference near Cambridge, primarily for pharmacists and nurses working in the fields of immunoglobulin therapy, immunology, haematology or neurology, however the event is open to any registered healthcare professional. The aim of the conference is to build skills to support effective patient care and, by improving the understanding of treatment, improve patient monitoring, dosing protocols and implementation of national and regional strategies.
News and updates
December 2025
Deadline to complete SCIG and Homecare Switches
National Ig Database meeting (12th Dec)
October 2025
Revised EOEIAP website launched
Update to Reserve Framework access published
September 2025
Deadline for IVIG switches (implementation of NHS Framework)
April 2025
Core Practice Standards version 2 published
March 2025
Clinical guidelines updated in line with v2 of the NHS England Clinical Commissioning Policy
November 2024
Inclusion of the eReferral walk-through prior to regional implementationUpdate to include NHSE CCG for scleromyxedemaDosing review (whole document)
October 2024
Updated advice in line with UKHSA guidelines for varicella zoster post exposure prophylaxisMinor amendment to Core Practice Standards (v1.8)
September 2024
Gamten 10% - UK plasma-sourced 10% IVIG is in production. UK plasma has arrived at the fractionation plant. Gamten is anticipated to be commercially available in early 2025. Sub-Regional Immunoglobulin Panels will be instrumental in integrating this new product safely into services and hospitals while maintaining patient treatments and use of all products approved in the NHSE immunoglobulin frameworks.
May 2024
Clinical guidelines alignment with newly published NHS Commissioning Policy. Note that weight-based dosing guidelines are under review and are not yet recommended for EOEIAP affiliated centres.
April 2024
Update to solid organ transplant indications (re: liver transplant) for AIT and AMRUpdate to use of commercial vs. UKHSA stocks for PEP
March 2024
Link to UKHSA document viral illness in pregnancy. Additional advice re: treatment of neonates born to mothers with measles.
February 2024
Updated links to current National Measles Guideline and updated dosing advice for IVIG and SCIG in immunosuppressed or at risk individuals following exposure to measles.
January 2023
Links updated to maintain fixed URL.Update to immunodeficiencies request form to capture CAR-T treatment data.
December 2023
Update to the clinical guideline for the management of measles, polio, hepatitis A or VZV using HNIgUpdate to Core Practice Standards to provide advice on clinical trials involving immunoglobulins
November 2023
House of Lords publishes report into Homecare Medicines Serviceshttps://committees.parliament.uk/work/7739/homecare-medicines-services/ (opens in a new tab)
October 2023
Revised clinical criteria for Catastrophic Antiphospholipid Syndrome publishedSeptember 202314th Sept - The inaugural combined ERINN and EOEIAP affiliated pharmacist regional education and update day at Madingley Hall
November 2022
Supporting the organisational transition at Cambridge University Hospitals from "@addenbrookes.nhs.uk" to "nhs.net" email accounts, contact details on this webpage have been updated.
August 2022
Updated treatment request form (immunomodulation) updated with 2022 abbreviated indications, dosing and commissioning statusRevisions to Core Practice Standards published to reflect current commissioning position and approval processes
July 2022
Revisions to EOE clinical guidelines including published NICE CG and TA. PHE now UK Health Security Agency: references amended. See end of guidelines for a complete list of revisions.
December 2021
Major revisions to NHS England commissioning documents for polyvalent IgG.
July 2021
New 18 month NHS Framework launched. Significant shortages globally of immunoglobulins that will affect the NHS. Mitigation plans in preparation.
April 2021
Update to clinical guidelines for the following conditions: Treatment of measles and Covid-vaccine associated thrombosis and thrombocytopenia
March 2021
All Trusts must now notify the EOEIAP of all immunoglobulin use either for approval or retrospectively for Class 1
February 2021
UK Plasma now sanctioned for the manufacture of immunoglobulins (GOV.uk) (opens in a new tab)